{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T04:03:00Z","timestamp":1774843380925,"version":"3.50.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["TRR 241"],"award-info":[{"award-number":["TRR 241"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["SFB 1340"],"award-info":[{"award-number":["SFB 1340"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This review provides guidance in the decision-making process regarding when to choose a janus kinase [JAK] inhibitor as medical treatment strategy. The focus will be on ulcerative colitis, because the only yet available JAK inhibitor, tofacitinib, has approval for use in ulcerative colitis. The guidance path will include consideration of disease activity, previous treatment, comorbidities, family planning, patient preferences, pharmacology as well as concurrent chronic inflammatory diseases or extraintestinal manifestations. The suggested guidance path illustrates our daily difficulties in the decision-making process regarding best choice for the individual patient. However if predictive biomarkers are lacking, the named criteria can be applied to any other strategy and hence provide support in daily practice.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaa003","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T20:09:46Z","timestamp":1578600586000},"page":"S761-S766","source":"Crossref","is-referenced-by-count":10,"title":["Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-958X","authenticated-orcid":false,"given":"Britta","family":"Siegmund","sequence":"first","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Department for Medicine (Gastroenterology, Infectious diseases, Rheumatology), Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"2020080105370526000_CIT0001","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2020080105370526000_CIT0002","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2020080105370526000_CIT0003","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2020080105370526000_CIT0004","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2020080105370526000_CIT0005","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2020080105370526000_CIT0006","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"2020080105370526000_CIT0007","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2020080105370526000_CIT0008","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.3462","article-title":"In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn\u2019s disease","volume":"20","author":"Atreya","year":"2014","journal-title":"Nat Med"},{"key":"2020080105370526000_CIT0009","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"2020080105370526000_CIT0010","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"2020080105370526000_CIT0011","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"2020080105370526000_CIT0012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020080105370526000_CIT0013","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","article-title":"Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies","volume":"12","author":"Pan\u00e9s","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2020080105370526000_CIT0014","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2020080105370526000_CIT0015","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/ibd\/izy387","article-title":"Using number needed to harm to put the risk of herpes zoster from tofacitinib in perspective","volume":"25","author":"Caldera","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2020080105370526000_CIT0016","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","article-title":"Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020080105370526000_CIT0017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/apt.12182","article-title":"Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease","volume":"37","author":"Long","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2020080105370526000_CIT0018","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.ejcn.1601049","article-title":"Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls","volume":"54","author":"Geerling","year":"2000","journal-title":"Eur J Clin Nutr"},{"key":"2020080105370526000_CIT0019","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.tcm.2015.03.010","article-title":"Inflammatory bowel disease and risk of coronary heart disease","volume":"25","author":"Rungoe","year":"2015","journal-title":"Trends Cardiovasc Med"},{"key":"2020080105370526000_CIT0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.crohns.2011.01.011","article-title":"Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients","volume":"5","author":"Sridhar","year":"2011","journal-title":"J Crohns Colitis"},{"key":"2020080105370526000_CIT0021","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020080105370526000_CIT0022","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/art.39267","article-title":"Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study","volume":"67","author":"Mantel","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2020080105370526000_CIT0023","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2020080105370526000_CIT0024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020080105370526000_CIT0025","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2020080105370526000_CIT0026","year":"2019"},{"key":"2020080105370526000_CIT0027","year":"2019"},{"key":"2020080105370526000_CIT0028","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(09)61963-2","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study","volume":"375","author":"Grainge","year":"2010","journal-title":"Lancet"},{"key":"2020080105370526000_CIT0029","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2020080105370526000_CIT0030","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"2020080105370526000_CIT0031","year":"2018"},{"key":"2020080105370526000_CIT0032","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020080105370526000_CIT0033","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/BOR.0000000000000301","article-title":"Targeting the interleukin-23\/17 axis in axial spondyloarthritis","volume":"28","author":"Paine","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2020080105370526000_CIT0034","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MOH.0000000000000320","article-title":"\u2018JAK-ing\u2019 up the treatment of primary myelofibrosis: building better combination strategies","volume":"24","author":"Assi","year":"2017","journal-title":"Curr Opin Hematol"},{"key":"2020080105370526000_CIT0035","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"2020080105370526000_CIT0036","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020080105370526000_CIT0037","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"2020080105370526000_CIT0038","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"2020080105370526000_CIT0039","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","article-title":"Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis","volume":"27","author":"Bauermann","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"2020080105370526000_CIT0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2020080105370526000_CIT0041","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/ajg.2015.321","article-title":"Inflammatory bowel disease patients\u2019 willingness to accept medication risk to avoid future disease relapse","volume":"110","author":"Bewtra","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2020080105370526000_CIT0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-10-1","article-title":"How do patients with inflammatory bowel disease want their biological therapy administered?","volume":"10","author":"Allen","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"2020080105370526000_CIT0043","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ibd\/izz253","article-title":"Risk factors for medication nonadherence to self-injectable biologic therapy in adult patients with inflammatory bowel disease","volume":"26","author":"Shah","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2020080105370526000_CIT0044","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/ecco-jcc\/jjx062","article-title":"Patient education in a 14-month randomised trial fails to improve adherence in ulcerative colitis: influence of demographic and clinical parameters on non-adherence","volume":"11","author":"Nikolaus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2020080105370526000_CIT0045","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/ecco-jcc\/jjy122","article-title":"Pharmacokinetics and immune reconstitution following discontinuation of thiopurine analogues: implications for drug withdrawal strategies","volume":"12","author":"Ben-Horin","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2020080105370526000_CIT0046","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","article-title":"Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis","volume":"58","author":"Dalrymple","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020080105370526000_CIT0047","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/cei.13112","article-title":"Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab","volume":"192","author":"Gorovits","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"2020080105370526000_CIT0048","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"2020080105370526000_CIT0049","doi-asserted-by":"crossref","first-page":"1756284818772786","DOI":"10.1177\/1756284818772786","article-title":"Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions","volume":"11","author":"Ward","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"2020080105370526000_CIT0050","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"2020080105370526000_CIT0051","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa003\/31785875\/jjaa003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/Supplement_2\/S761\/33556872\/jjaa003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/Supplement_2\/S761\/33556872\/jjaa003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T09:37:28Z","timestamp":1596274648000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/Supplement_2\/S761\/5699824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":51,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2020,1,10]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa003","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,1,10]]}}}